Home
    • Plans Blog Contact
    Compugen logo

    Compugen

    CGEN
    Last price US$2.41
    Market cap US$215.6m
    12M price change 66.21%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Compugen Overview

    Industry: Biotechnology

    Sector: Healthcare

    Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with nave head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I cl Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Compugen into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 03, 2026

    Quarterly result summary

    Exhibit 99.1 August 3, 2026 Dear Shareholder, You are cordially invited to attend, and notice is hereby given of, the 2026 Annual General Meeting of Shareholders of Compugen Ltd. (the “ Company ”) to be held at the Company’s offices at 26 Harokmim Street, Bld...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 6-K Aug 03, 2026 Earnings release EXHIBIT 99.1 Aug 03, 2026 Earnings release EXHIBTI 99.3 Aug 03, 2026 Earnings release EXHIBIT 99.1 May 18, 2026 SEC filing ZK2635352 May 18, 2026 SEC filing 20-F Mar 02, 2026 SEC filing 6-K Mar 02, 2026 Earnings release EXHIBIT 99.1 Mar 02, 2026 SEC filing 6-K Feb 12, 2026 SEC filing 6-K Dec 17, 2025 SEC filing 6-K Nov 10, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 4.00/5
    Compugen boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.65/5
    Compugen exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Compugen CGEN US$215.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.95/5
    Compugen olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Compugen CGEN US$215.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.82/5
    Compugen attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Compugen CGEN US$215.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Compugen logo

    Compugen

    US$2.41

    US$4.91

    +103.6% vs price

    US$215.6m

    0.21%

    66.21%